UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UBS Group
UBS
|
+$3.78B |
| 2 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$718M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$218M |
| 4 |
Union Pacific
UNP
|
+$210M |
| 5 |
Alcon
ALC
|
+$185M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$820M |
| 2 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$604M |
| 3 |
Apple
AAPL
|
+$598M |
| 4 |
iShares MSCI ACWI ETF
ACWI
|
+$524M |
| 5 |
TSMC
TSM
|
+$324M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.29% |
| 2 | Financials | 8.09% |
| 3 | Healthcare | 6.75% |
| 4 | Consumer Discretionary | 5.04% |
| 5 | Industrials | 4.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3001
AXIS Capital
AXS
$7.62B
| $3M | ﹤0.01% |
55,100
+8,387
| +18% | +$487K |
|
3002
iShares iBonds Dec 2032 Term Corporate ETF
IBDX
$1.71B
| $3M | ﹤0.01% |
119,652
+119,612
| +299,030% | +$2.96M |
|
|
CERE
3003
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $3M | ﹤0.01% |
122,975
+8,537
| +7% | +$251K |
|
3004
New York Times
NYT
$10.5B
| $3M | ﹤0.01% |
77,107
+63,047
| +448% | +$2.32M |
|
|
FOLD
3005
DELISTED
Amicus Therapeutics
FOLD
| $3M | ﹤0.01% |
270,247
-306,104
| -53% | -$3.77M |
|
3006
Revolution Medicines
RVMD
$42.1B
| $3M | ﹤0.01% |
138,361
-29,282
| -17% | -$721K |
|
3007
Atlassian
TEAM
$28B
| $2.99M | ﹤0.01% |
17,477
-23,800
| -58% | -$3.8M |
|
3008
BioXcel Therapeutics
BTAI
$25.6M
| $2.99M | ﹤0.01% |
10,018
+1,317
| +15% | +$562K |
|
3009
Sibanye-Stillwater
SBSW
$7B
| $2.99M | ﹤0.01% |
359,377
+19,224
| +6% | +$186K |
|
3010
Prothena Corp
PRTA
$449M
| $2.99M | ﹤0.01% |
61,643
-29,426
| -32% | -$1.55M |
|
3011
Invesco Global Water ETF
PIO
$283M
| $2.98M | ﹤0.01% |
85,245
-6,114
| -7% | -$212K |
|
|
RCM
3012
DELISTED
R1 RCM Inc. Common Stock
RCM
| $2.98M | ﹤0.01% |
198,784
-114,197
| -36% | -$1.56M |
|
3013
CBIZ
CBZ
$2.96B
| $2.97M | ﹤0.01% |
60,042
+5,269
| +10% | +$254K |
|
|
CADE
3014
DELISTED
Cadence Bank
CADE
| $2.95M | ﹤0.01% |
142,316
+42,246
| +42% | +$1.05M |
|
3015
Coca-Cola Consolidated
COKE
$12.5B
| $2.95M | ﹤0.01% |
55,190
-151,860
| -73% | -$7.84M |
|
3016
Insmed
INSM
$28.7B
| $2.94M | ﹤0.01% |
172,705
-134,193
| -44% | -$2.61M |
|
3017
Sonoco
SON
$5.64B
| $2.94M | ﹤0.01% |
48,272
+12,573
| +35% | +$746K |
|
3018
Healthcare Realty
HR
$6.92B
| $2.94M | ﹤0.01% |
152,266
-151,108
| -50% | -$3.04M |
|
3019
Ferguson
FERG
$49.1B
| $2.94M | ﹤0.01% |
21,997
-317,354
| -94% | -$44.1M |
|
3020
UiPath
PATH
$7.25B
| $2.94M | ﹤0.01% |
167,516
+87,942
| +111% | +$1.33M |
|
3021
LXP Industrial Trust
LXP
$3.57B
| $2.94M | ﹤0.01% |
56,999
-5,535
| -9% | -$296K |
|
3022
Denali Therapeutics
DNLI
$3.92B
| $2.93M | ﹤0.01% |
127,351
+7,170
| +6% | +$197K |
|
3023
Davis Select Financial ETF
DFNL
$491M
| $2.93M | ﹤0.01% |
112,996
-6,494
| -5% | -$182K |
|
3024
iShares Global Financials ETF
IXG
$686M
| $2.93M | ﹤0.01% |
42,494
-19,273
| -31% | -$1.41M |
|
3025
CALL
Archrock
AROC
$5.84B
| $2.93M | ﹤0.01% |
+300,000
| New | +$2.94M |
|
Similar funds
UBS Group's Q1 2023 Portfolio in Review
As of Q1 2023, UBS Group held 11,664 positions worth $274B, up 2.2% from $268B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
UBS Group withdrew a net $10.4B in Q1 2023, closing 2,127 positions and reducing 4,260 holdings. Its most notable exit was LHC Group LLC, an estimated $49M position sold in full.
By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 11% a quarter earlier, followed by Financials and Healthcare.
Against the trend, UBS Group opened a new position in First Trust Nasdaq Oil & Gas ETF worth $13.3M.
- UBS Group's largest Q1 2023 buy was First Trust Nasdaq Oil & Gas ETF: 493,205 shares worth $13.3M.
- UBS Group added most to UBS Group in Q1 2023, an estimated $3.78B increase.
- UBS Group's biggest Q1 2023 reduction was Microsoft, cutting an estimated $820M.
- UBS Group fully exited LHC Group LLC in Q1 2023, selling an estimated $49M.
- UBS Group's ten largest holdings make up 16% of its $274B portfolio in Q1 2023.
- UBS Group opened 983 new positions and closed 2,127 in Q1 2023.
- UBS Group's portfolio value rose 2.2% quarter-over-quarter to $274B.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.